Euclises Pharmaceuticals

Developer of superior efficacy cancer therapeutics

placeSaint Louis, Missouri, United States calendar_todayFounded 2011 language euclises.com

Innovation

7 patent families (4 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 248 times.

YearFilings
20142
20155
20161
20172
20181
20192
20201
20212
20221
20231
20251
20261

Investor mix

8 investors on record; lead investors include St. Louis Arch Angels.

Investor typeCountShare
Venture capital563%
Angel & family office113%
Other / undisclosed225%
Coming soon